Calidi Biotherapeutics reports Q2 2024 net loss of $5.8M; cash at $1.0M; launches Nova Cell subsidiary

Calidi Biotherapeutics, Inc.

2024-Q2 EPS reported -$3.30

Net loss of $5.8M ($1.40 per share) vs. $12.5M loss ($14.24 per share) in Q2 2023.
Cash and restricted cash total ~$1.0M as of June 30, 2024, down from $2.1M at Dec 31, 2023.
Launched Nova Cell subsidiary with $2M investment from Dr. Ronald Rigor; received additional $1M into Calidi.
Appointed Dr. George Peoples to Board of Directors and Dr. Mark Gilbert to Medical Advisory Board.
Received new U.S. patent for SuperNova technology; raised $2.5M from warrant exercises in July/August 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.